BRISBANE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended June 30, 2025 and provided a corporate update.
Related Questions
Are there any notable changes in operating expenses or R&D spending that could affect future profitability?
What is the market's reaction to the earnings release and business update on social and institutional platforms?
What are the implications of the Q2 results for Tempest's long‑term growth strategy and valuation?
What were Tempest Therapeutics' revenue and net loss for Q2 2025, and how do they compare to prior quarters?
How did the cash balance and runway change in this quarter's report?
What are the key updates on the clinical trial progress for Tempest's lead candidates?
Did the company provide any guidance or outlook for upcoming quarters or FY 2025?
How might the Q2 results impact Tempest Therapeutics' stock price in the short term?
What are the potential regulatory or partnership developments mentioned in the business update?
How does Tempest's Q2 performance compare to other biotech peers in the same therapeutic area?